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ABSTRACT
Objective: The proposed method describes method development and validation of nebivolol hydrochloride and cilnidipine in combined pharmaceutical 
tablet dosage form by high-performance thin-layer chromatography (HPTLC) having adequate specificity, sensitivity, and reproducibility.
Methods: Nebivolol hydrochloride and cilnidipine drug combination is used for the treatment of hypertension. Precoated aluminum plates with silica 
gel 60 F254 (E-Merck, Germany) were used for the chromatographic separation which was carried using chloroform:glacial acetic acid:methanol, in 
8.5:1:0.5 (v/v/v) as a mobile phase. HPTLC separation of two drugs was carried by densitometric measurement at 270 nm.
Reults: The drugs were satisfactorily resolved with retardation factor values of 0.0.29±0.008 and 0.69±0.007 for nebivolol hydrochloride and 
cilnidipine, respectively. The method was found to be linear in the range of 100–1000 ng/spot and 50–500 ng/spot for nebivolol hydrochloride and 
cilnidipine, respectively. The correlation coefficient was found to be 0.989 and 0.996 for nebivolol hydrochloride and cilnidipine, respectively. Limit of 
detection and limit of quantitation values were 16.395 ng/band and 49.681 ng/band and 31.788ng/band and 96.328 ng/band, respectively. The mean 
recovery was found to be 100.570–101.936 and 100.269–101.333 for nebivolol hydrochloride and cilnidipine, respectively. The intra- and inter-day 
precision was found to be within the limit.
Conclusion: A simple, accurate, precise, and sensitive HPTLC method has been developed and validated in combined pharmaceutical tablet dosage 
form for simultaneous estimation of nebivolol hydrochloride and cilnidipine.
Keywords: Method development high-performance thin-layer chromatography, Nebivolol hydrochloride, Cilnidipine, International Council for 
Harmonisation.
INTRODUCTION
Hypertension is a disease characterized by abnormal elevation 
of blood pressure (BP) in the arteries. It is broadly classified as 
primary and secondary. About 90–95% of cases are termed as 
primary (idiopathic) hypertension, which refers to high BP for which 
no exact cause can be found. The remaining 5–10% of secondary 
hypertension can be caused by conditions that affect your kidneys, 
arteries, heart or endocrine system. Prevention and control of high 
BP are the main focuses for reducing the severity of cardiovascular 
diseases [1].
Combination of drugs such as nebivolol HCl and cilnidipine has 
been prescribed to manage hypertension [2]. Nebivolol HCl 
(1RS,1′RS)-1,1′-[(2RS,2′SR)-bis(6-fluoro-3,4-dihydro-2H-1-
benzopyran-2-yl)]- 2,2′-iminodiethanol hydrochloride [3] is a highly 
selective β1-blocker with nitric oxide-mediated vasodilatory actions 
and beneficial effects on vascular endothelial function.
Cilnidipine is a dihydropyridine calcium channel blocker. It is a dual blocker 
of L-type voltage-gated calcium channels in vascular smooth muscle and 
N-type calcium channels in sympathetic nerve terminals that supply blood 
vessels [4]. This combination is launched in the market under brand name 
Ln Beta, manufactured by Eris Lifesciences Pvt. Ltd., Ahmedabad.
It was found that UV spectroscopic, stability-indicating RP-HPLC, HPLC, 
and bioanalytical methods have been reported for analysis of these two 
drugs in combination [5-12]. However, there is only one paper reported 
for the analysis of the combination by high-performance thin-layer 
chromatography (HPTLC) [13].
In view of the need for a suitable method for routine analysis in combined 
formulations, attempts are being made to develop simple, precise, 
accurate, rapid, economical, and reproducible analytical methods for the 
simultaneous estimation of nebivolol HCl and cilnidipine and extend it to 
their determination in the formulation. The work deals with development 
and validation of HPTLC method for the estimation of nebivolol HCl and 
cilnidipine by HPTLC in accordance with the International Council for 
Harmonisation (ICH) guidelines for analytical application.
Nebivolol hydrochloride and cilnidipine were a generous gift by Actavis 
Pharmaceuticals Ltd., Mumbai, India and Prayosha Healthcare Pvt. 
Ltd., Ankleshwar, India, respectively. Chloroform, glacial acetic acid, 
methanol, and all other chemicals used were of analytical reagent grade.
Equipment
The instruments used in the study were Camag HPTLC 
system comprising Linomat-5 applicator, Camag thin-layer 
chromatography scanner 3, Win Computer-Aided Transcription 
System software (Version 1.4.3, Camag), aluminum plates 
precoated with silica gel 60 F254 (E-Merck, Germany), Hamilton 
syringe (100 μl), and Deuterium lamp which was used as a 
radiation source. Shimadzu balance model AY-120, hot air 
oven (Kumar Laboratory Oven), photostability chamber (Make 
Newtronic. Model IC DAC version 1.2), and calibrated glass wares 
were used for the study.
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Standard solution preparation and selection of analytical 
wavelength
Stock solution for cilnidipine and nebivolol hydrochloride was prepared by 
dissolving 10 mg of drug in 10 ml methanol. Further dilution of nebivolol 
hydrochloride and cilnidipine stock solution was made using methanol to 
get the standard solution having 100 µg/mL and 50 µg/mL, respectively.
From the standard stock solution, further dilutions were done using 
methanol and scanned over the range of 200–400 nm, and the spectra 
were obtained. It was observed that both drugs showed considerable 
absorbance at 270 nm.
Chromatographic conditions
Samples were applied on the 10 cm × 10 cm plate as a band with a width of 
6 mm and slit dimensions were kept as 4.00 × 0.45 mm. Chamber saturation 
time was 20 min and the migration distance was 80 mm. Mobile phase used 
was chloroform:glacial acetic acid:methanol, in 8.5:1:0.5 (v/v/v) ratio.
Analysis of tablet formulation
Twenty tablets were weighed accurately and finely powdered. A quantity 
of powder equivalent to 10 mg of cilnidipine (5 mg of Nebivolol 
hydrochloride) was weighed and transferred to a 10 ml volumetric flask 
containing about 5 ml of methanol and shaken for 5 min, and volume was 
made up with the methanol. The solution was filtered using Whatman 
paper No. 41, and 1 ml filtrate was further diluted to 10 ml with methanol 
to get sample stock solution of 100 ng/µl of cilnidipine and 50 ng/µl of 
nebivolol hydrochlordie. 2 ml of sample solution was applied on HPTLC 
plate to obtain a final concentration of 200 ng/band of cilnidipine and 
100 ng/band of nebivolol. After chromatographic development, peak 
areas of the bands were measured at 270 nm and concentration of drug 
in the sample was estimated from the calibration curves. Procedure was 
repeated 6 times for the analysis of homogenous sample.
METHOD VALIDATION [14]
The method was validated as per the ICH guidelines.
Linearity
The standard stock solution of cilnidipine (100 ng/µl) and nebivolol 
hydrochloride (50 ng/µl) was applied as over spotting on HPTLC plate 
Fig 3: Calibration curve for cilnidipine
Fig. 1: Densitogram of nebivolol HCl (100 ng/band) and 
cilnidipine (200 ng/band)
Fig 2: Calibration curve for nebivolol HCl













1 100 4686 50 3955.4
2 200 5825.4 100 4981.6
3 400 7061 200 6126.4
4 600 8553.1 300 7132.2
5 800 9839.8 400 8770.6
6 1000 11521.5 500 9496.6
Table 3: Statistical validation of intra‑ and inter‑day precision 
studies
Component Precision % of Label 
claim
SD % RSD
Cilnidipine Intraday (n=6) 101.128 0.961 0.009
Interday (n=3×3) 100.003 1.115 0.011
Nebivolol 
HCl
Intraday (n=6) 101.260 1.517 0.014
Interday (n=3×3) 100.675 1.046 0.010
RSD: Reflex sympathetic dystrophy, SD: Standard deviation, HCl: Hydrochloride
Table 2: Regression analysis of calibration curves of nebivolol 
HCl and cilnidipine
Parameter Cilnidipine Nebivolol HCl
Detection Wavelength (nm) 270 270
Linearity range (ng/band) 100-1000 50-500
Correlation coefficient (r) 0.996 0.989
Linear regression equationa 
(y=mx+c)
Intercept (c) 4136.3 3576.7
Slope (m) 7.312 12.26
HCl: Hydrochloride
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in range of 1–10 µl with the help of CAMAG 100 µL sample syringe, 
using Linomat 5 sample applicator to obtain final concentration 
100–1000 ng/band for cilnidipine and 50–500 ng/band for nebivolol 
hydrochlordie. The plate was developed and scanned under the 
above established chromatographic conditions. Each standard in six 
replicates was analyzed, and peak areas were recorded. Calibration 
curves of cilnidipine and nebivolol hydrochloride were plotted of peak 
area versus concentration.
Intra‑ and inter‑day precision
The precision of the method was demonstrated by intra- and inter-day 
variation studies. In the intraday studies, six replicates of standard 
solution (200 ng/band for cilnidipine and 100 ng/band for nebivolol 
hydrochloride – Assay Concentration) were analyzed in a day and 
percentage reflex sympathetic dystrophy (RSD) was calculated. For the 
interday variation studies, three replicates of standard solutions (200, 
400, and 600 ng/band for cilnidipine and 100, 200, and 300 ng/band 
for nebivolol) were analyzed on 3 consecutive days and percentage RSD 
was calculated.
Accuracy
To check the accuracy of the method, recovery studies were carried 
out by over spotting standard drug solution to pre-analyzed sample 
solution at three different levels of 50, 100, and 150%. The basic 
concentration of sample chosen was 200 ng/band for cilnidipine and 
100 ng/band for nebivolol hydrochloride. The areas were noted after 
the development of plate. The drug concentration was calculated using 
regression equations.
Limit of detection (LOD)
LOD was calculated from the following formula: 
LOD= 3.3 �/S
Where
� = Standard deviation of the response (y-intercept)
S = Slope of the calibration curve
Limit of quantitation (LOQ)
LOQ was calculated from the following formula: 
LOQ= 10 �/S
Where
�= Standard deviation of the response (y-intercept)
S = Slope of the calibration curve
Robustness
The robustness of the method was studied, during method development, 
by small but deliberate variations in time from application to 
development (0, 30, and 60 min) and time from development to scanning 
(0, 30, and 60). One factor at a time was changed at a concentration 
level of 200 ng/band for cilnidipine and 100 ng/band for nebivolol 
hydrochloride to study the effect on the peak area of the drugs.
RESULTS AND DISCUSSION
The standard densitograms of nebivolol hydrochloride and cilnidipine 
are shown in Fig. 1.
Nebivolol retardation factor (Rf) = 0.29±0.008
Cilnidipine Rf = 0.69±0.007
Linearity
The linearity data for calibration curve is shown in Table 1, the 
calibration curve for nebivolol hydrochloride and cilnidipine is shown 
in Figs. 2 and 3, respectively, and the regression data are shown in 
Table 2.
The results for precision studies and accuracy are shown in 
Tables 3 and 4.The results for LOD and LOQ for nebivolol hydrochloride 
and cilnidipine are shown in Table 5.The robustness data are shown in 
Table 6.
Analysis of tablet formulation
After chromatographic development, peak areas of the bands were 
measured at 270 nm and concentration of drug in the sample was 
estimated from the calibration curves. The procedure was repeated 
6 times for the analysis of homogenous sample. The results for tablet 
analysis are shown in Table 7.
DISCUSSION
HPTLC method for the determination of nebivolol hydrochloride and 
cilnidipine was developed. Linearity for nebivolol hydrochloride 
and cilnidipine was found in the range of 100–1000 ng/band and 
50–500 ng/band and regression coefficient (r²) = 0.989 and 0.986, 
Table 4: Recovery studies of nebivolol HCl and cilnidipine (n=3)
Drug Amount taken (ng per band) Amount added (ng/band) Total amount (ng/band) % Recovery* % RSD*
Nebivolol 
hydrochloride
100 50 150 100.696 1.396
100 100 200 101.936 1.137
100 150 250 100.570 1.744
Cilnidipine 200 100 300 100.269 0.869
200 200 400 101.333 1.685
200 300 500 100.849 1.445
RSD: Reflex sympathetic dystrophy, HCl: Hydrochloride
Table 5: LOD and LOQ
Parameters Nebivolol hydrochloride Cilnidipine
LOD (ng/band) 16.395 31.788
LOQ (ng/band) 49.681 96.328
LOD: Limit of Detection, LOQ: Limit of Quantitiation
Table 6: Robustness data in terms of % RSD (n=3)
Sr. 
No




1 Time from application 
to development
0, 30, and 
60 min
0.099 0.054
2 Time from development 
to scanning
0, 30, and 
60 min
0.057 0.028
RSD: Reflex sympathetic dystrophy
Table 7: Analysis of tablet formulation by HPTLC
Drug Label claim 
(mg/tablet)




Cilnidipine 10 101.417 1.799 0.017
Nebivolol 
hydrochloride
5 100.955 1.565 0.015
*Average of six determinations. HPTLC: High-performance thin-layer 
chromatography, RSD: Reflex sympathetic dystrophy
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respectively. It indicates that the proposed method found to be linear. 
LOD and LOQ values were 16.395 ng/band and 49.681 ng/band and 
49.681 ng/band and 96.328 ng/band, respectively, and this low value of 
LOD and LOQ indicates that the proposed method is sensitive. The RSD 
values for intra- and inter-day precision studies were found to be <2%; 
this low value of RSD indicates that the proposed method is precise.
CONCLUSION
A new, simple, and sensitive HPTLC method has been successfully 
developed and validated for simultaneous determination of nebivolol 
hydrochloride and cilnidipine in bulk and pharmaceutical dosage form. 
The method was found to be accurate, precise, and economic and hence 
can be used for routine analysis of the drugs in combination.
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